Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to ctnnb1 alterations

Journal of the National Cancer Institute

Volumn 105, Issue 24, 2013, Pages 1852-1861

  Nan, Hongmei ^a,b   Morikawa, Teppei ^d,e   Suuriniemi, Miia ^e   Imamura, Yu ^d,e   Werner, Lillian ^e   Kuchiba, Aya ^d,e   Yamauchi, Mai ^d,e   Hunter, David J ^b,c,e,f,g   Kraft, Peter ^c   Giovannucci, Edward L ^b,c,e,f,g   Fuchs, Charles S ^b,e   Ogino, Shuji ^c,d,e,f   Freedman, Matthew L ^e,h   Chan, Andrew T ^b,i  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b CHANNING LABORATORY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Center for Molecular Oncology   (United States)

^e Department of Medical Oncology ^*  (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h BROAD INSTITUTE OF MIT AND HARVARD   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA CATENIN; GUANINE; NONSTEROID ANTIINFLAMMATORY AGENT; THREONINE;

AGE DISTRIBUTION; AGED; ALLELE; ARTICLE; BINDING AFFINITY; BODY MASS; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; CHROMOSOME 8Q; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACE DIFFERENCE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; WNT SIGNALING PATHWAY;

EID: 84891449924     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt331     Document Type: Article

References (53)

1. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294(8):914-923.
2. Friis S, Poulsen AH, Sorensen HT, et al. Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: a Danish cohort study. Cancer Causes Control. 2009;20(5):731-740.
3. Garcia Rodriguez LA, Huerta-Alvarez C. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology. 2000;11(4):376-381.
4. La Vecchia C, Negri E, Franceschi S, et al. Aspirin and colorectal cancer. Br J Cancer. 1997;76(5):675-677.
5. Sandler RS, Galanko JC, Murray SC, et al. Aspirin and nonsteroidal antiinflammatory agents and risk for colorectal adenomas. Gastroenterology. 1998;114(3):441-447.
6. Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978;61(2):314-319.
7. Greenhough A, Smartt HJ, Moore AE, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009;30(3):377-386.
8. Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373-2383.
9. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci. 2003;24(2):96-102.
10. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356(21):2131-2142.
11. Bos CL, Kodach LL, van den Brink GR, et al. Effect of aspirin on the WNT/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene. 2006;25(49):6447-6456.
12. Dihlmann S, Siermann A, von Knebel Doeberitz M. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 2001;20(5):645-653.
13. Kishimoto Y, Takata N, Jinnai T, et al. Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane. Gut. 2000;47(6):812-819.
14. Castellone MD, Teramoto H, Gutkind JS. Cyclooxygenase-2 and colorectal cancer chemoprevention: the beta-catenin connection. Cancer Res. 2006;66(23):11085-11088.
15. Castellone MD, Teramoto H, Williams BO, et al. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science. 2005;310(5753):1504-1510.
16. Tenesa A, Farrington SM, Prendergast JG, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet. 2008;40(5):631-637.
17. Tomlinson I, Webb E, Carvajal-Carmona L, et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet. 2007;39(8):984-948.
18. Zanke BW, Greenwood CM, Rangrej J, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet. 2007;39(8):989-994.
19. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509-1512.
20. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell. 2000;103(2):311-320.
21. Pomerantz MM, Ahmadiyeh N, Jia L, et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet. 2009;41(8):882-884.
22. Tuupanen S, Turunen M, Lehtonen R, et al. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet. 2009;41(8):885-890.
23. Sur IK, Hallikas O, Vaharautio A, et al. Mice lacking a Myc enhancer that includes human SNP rs6983267 are resistant to intestinal tumors. Science. 2012;338(6112):1360-1363.
24. Morikawa T, Kuchiba A, Yamauchi M, et al. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA. 2011;305(16):1685-1694.
25. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351(25):2599-2610.
26. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333(10):609-614.
27. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121(4):241-246.
28. Morikawa T, Kuchiba A, Lochhead P, et al. Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with beta-catenin (CTNNB1) status. Cancer Res. 2013;73(5):1600-1610.
29. Hu FB, Stampfer MJ, Rimm E, et al. Dietary fat and coronary heart disease: a comparison of approaches for adjusting for total energy intake and modeling repeated dietary measurements. Am J Epidemiol. 1999;149(6):531-540.
30. Haiman CA, Le Marchand L, Yamamato J, et al. A common genetic risk factor for colorectal and prostate cancer. Nat Genet. 2007;39(8):954-956.
31. Wright JB, Brown SJ, Cole MD. Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. Mol Cell Biol. 2010;30(6):1411-1420.
32. Gardner SH, Hawcroft G, Hull MA. Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells. Br J Cancer. 2004;91(1):153-163.
33. Sur IK, Hallikas O, Vaharautio A, et al. Mice lacking a Myc enhancer that includes human SNP rs6983267 are resistant to intestinal tumors. Science. 2012;338(6112):1360-1363.
34. Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011;60(3):397-411.
35. Greenspan EJ, Madigan JP, Boardman LA, et al. Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. Cancer Prev Res (Phila). 2011;4(1):161-171.
36. Munemitsu S, Albert I, Souza B, et al. Regulation of intracellular betacatenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA. 1995;92(7):3046-3050.
37. Orford K, Crockett C, Jensen JP, et al. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J Biol Chem. 1997;272(40):24735-24738.
38. Boon EM, Keller JJ, Wormhoudt TA, et al. Sulindac targets nuclear betacatenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer. 2004;90(1):224-229.
39. Koornstra JJ, Rijcken FE, Oldenhuis CN, et al. Sulindac inhibits betacatenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1608-1612.
40. Cho M, Gwak J, Park S, et al. Diclofenac attenuates Wnt/beta-catenin signaling in colon cancer cells by activation of NF-kappaB. FEBS Lett. 2005;579(20):4213-4218.
41. Gardner SH, Hawcroft G, Hull MA. Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells. Br J Cancer. 2004;91(1):153-163.
42. Hawcroft G, D'Amico M, Albanese C, et al. Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis. 2002;23(1):107-114.
43. Rice PL, Kelloff J, Sullivan H, et al. Sulindac metabolites induce caspaseand proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther. 2003;2(9):885-892.
44. Tuynman JB, Vermeulen L, Boon EM, et al. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res. 2008;68(4):1213-1220.
45. Breslow NE, Day NE. Statistical methods in cancer research. IARC Workshop 25-27 May 1983. IARC Sci Publ. 1987:(82):1-406.
46. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology. 2008;134(1):21-28.
47. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348(10):891-899.
48. Benamouzig R, Uzzan B, Deyra J, et al. Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. Gut. 2012;61(2):255-261.
49. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2012;378(9809):2081-2087.
50. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on longterm risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31-41.
51. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348(10):883-890.
52. Hutter CM, Chang-Claude J, Slattery ML, et al. Characterization of geneenvironment interactions for colorectal cancer susceptibility loci. Cancer Res. 2012;72(8):2036-2044.
53. Hutter CM, Slattery ML, Duggan DJ, et al. Characterization of the association between 8q24 and colon cancer: gene-environment exploration and meta-analysis. BMC Cancer. 2010;10:670.